FoxHollow/Merck R&D Deal: The Value of Plaque

An unusual pharmacogenomics alliance between a device company a major pharmaceutical company opens up new markets for both partners.

By Stephen Levin

Atherosclerotic plaque is generally viewed not as a substance of value but as something to be eliminated. That is why...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from In Vivo Archive

More from In Vivo